Examkin

Soru

Zorluk: ZorHealthcare Economics and Value-Based Care

A health system's pharmacy and therapeutics committee is reviewing a cost-utility analysis for a novel immunotherapy being considered for the formulary to treat advanced non-small cell lung cancer. The novel agent will be compared to the current standard of care, a conventional chemotherapy regimen.

The health economist presents the following data regarding the total lifetime costs and clinical outcomes per patient for each treatment pathway:

Treatment PathwayTotal Lifetime CostAverage Life ExpectancyHealth-Related Quality of Life (Utility)
Conventional Chemotherapy$40,0002.5 years0.40
Novel Immunotherapy$190,0004.0 years0.75

The committee mandates that new therapies must not exceed a willingness-to-pay threshold of $100,000 per quality-adjusted life year (QALY) gained.

What is the incremental cost-effectiveness ratio (ICER) of the novel immunotherapy compared to conventional chemotherapy, expressed in dollars per QALY gained?

Cevap: 75000 $/QALY

Cevap

75000
The correct answer is derived by calculating the difference in costs between the two interventions and dividing it by the difference in their clinical benefits (measured in QALYs). The ICER formula is ICER=ΔCostΔQALYICER = \frac{\Delta Cost}{\Delta QALY}. By substituting the given values, the resulting ICER is 75,000, which falls well below the committee's $100,000 threshold, indicating it is a highly cost-effective intervention.

Adım Adım Çözüm

1
Calculate the Quality-Adjusted Life Years (QALYs) for the standard of care.
2.5 years×0.40=1.0 QALY2.5 \text{ years} \times 0.40 = 1.0 \text{ QALY}
QALY represents disease burden, factoring in both the quality and quantity of life lived. It is calculated by multiplying the life expectancy by the utility weight.
2
Calculate the Quality-Adjusted Life Years (QALYs) for the novel therapy.
4.0 years×0.75=3.0 QALYs4.0 \text{ years} \times 0.75 = 3.0 \text{ QALYs}
This determines the total health benefit provided by the new intervention.
3
Determine the incremental health benefit (ΔQALY\Delta QALY).
3.0−1.0=2.0 QALYs gained3.0 - 1.0 = 2.0 \text{ QALYs gained}
The denominator of the ICER equation requires the net difference in health outcomes between the two therapies.
4
Determine the incremental cost (ΔCost\Delta Cost).
190,000−$40,000=$150,000190,000 - \$40,000 = \$150,000
The numerator of the ICER equation requires the net financial difference between the two therapies.
5
Calculate the Incremental Cost-Effectiveness Ratio (ICER).
$150,0002.0 QALYs=75,000\frac{\$150,000}{2.0 \text{ QALYs}} = 75,000
The ICER represents the additional cost required to generate one additional year of perfect health.

Anahtar Kavram

The Incremental Cost-Effectiveness Ratio (ICER) is a fundamental metric in healthcare economics used to assess the value of a new medical intervention compared to the standard of care by measuring the additional cost per additional Quality-Adjusted Life Year (QALY) gained.
Bu soruyu puanla

Konular

Healthcare Economics and Value-Based Care

Bu konudan daha fazla soru